Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
305.02
-0.67 (-0.22%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
37
38
Next >
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
May 19, 2022
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses?
Via
Investor's Business Daily
7 Dividend Stocks to Boost Your Retirement Savings
May 19, 2022
This is a very good time to look for quality foundational stocks that not only have growth potential but are solid dividend stocks, too.
Via
InvestorPlace
Peering Into Amgen's Recent Short Interest
May 18, 2022
Amgen's (NASDAQ:AMGN) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 20.75 million shares sold short, which is 3.9% of all...
Via
Benzinga
5 Beaten-Down Blue-Chip Stocks to Buy Now
May 17, 2022
These are the best blue-chip stocks to buy now. MMM, AMGN, BA, JPM, and MSFT can make great investments in the coming months.
Via
InvestorPlace
Executives Sell More Than $220M Of 3 Stocks
May 11, 2022
US stock futures traded higher on this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
May 10, 2022
Keybanc cut PubMatic, Inc. (NASDAQ: PUBM) price target from $48 to $27. PubMatic shares fell 1.5% to $18.71 in pre-market trading.
Via
Benzinga
Why Amgen Shares Are Trading Lower
April 28, 2022
Amgen, Inc. (NASDAQ: AMGN) shares are trading lower by 6.21% at $233.33 after the company reported first-quarter earnings results.
Via
Benzinga
Where Amgen Stands With Analysts
April 28, 2022
Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following analyst ratings:
Via
Benzinga
Markets Sell Off Following Last Week's Federal Reserve Decision
May 09, 2022
U.S. indices fell sharply again Monday as stocks continued to sell off following last week’s Fed rate hike decision. A gain in Treasury yields has also weighed on technology and growth stocks.
Via
Benzinga
This Is What Whales Are Betting On Amgen
May 09, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 21 strange trades.
Via
Benzinga
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
May 07, 2022
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in...
Via
Talk Markets
Markets Close Turbulent Week On A Down Note
May 06, 2022
The S&P 500 traded lower in a roller coaster week on Wall Street as investors digested another Federal Reserve interest rate hike and a mixed batch of earnings reports.
Via
Benzinga
Biotech Behemoth Amgen Tops First-Quarter Views, But 2022 Guidance Lags
April 27, 2022
Amgen stock fell late Wednesday on a surprise in its 2022 outlook despite a strong first-quarter showing.
Via
Investor's Business Daily
9 Health Care Stocks With Whale Alerts In Today's Session
May 06, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
7 Defensive Dividend Healthcare Stocks to Buy Now
May 06, 2022
As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense.
Via
InvestorPlace
Analyzing Amgen's Short Interest
May 02, 2022
Amgen's (NASDAQ:AMGN) short percent of float has fallen 7.95% since its last report. The company recently reported that it has 22.52 million shares sold short, which is 4.05% of...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Here's How Much $100 Invested In Amgen 10 Years Ago Would Be Worth Today
April 29, 2022
Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.67%. Currently, Amgen has a market capitalization of...
Via
Benzinga
Major Indexes Log Best Day Since Early March
April 28, 2022
The major indexes enjoyed a strong rebound on Thursday, with the Dow settling with a more than 614-point gain, nabbing its biggest daily jump since March 9.
Via
Talk Markets
Markets Surge Despite Drop In US GDP
April 28, 2022
U.S. indices traded higher Thursday despite a drop in U.S. GDP. Strength in stocks is possibly due to better-than-expected quarterly earnings from multiple companies as well as a...
Via
Benzinga
Check Out What Whales Are Doing With AMGN
April 28, 2022
A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 18 strange trades.
Via
Benzinga
How is it going with the Big Biopharma Earnings Week?
April 28, 2022
Abbott and JNJ kicked off healthcare earnings last week and the results were just OK.
Via
Talk Markets
Piper Sandler Maintains Overweight Rating for Amgen: Here's What You Need To Know
April 28, 2022
Piper Sandler has decided to maintain its Overweight rating of Amgen (NASDAQ:AMGN) and raise its price target from $255.00 to $260.00. Shares of Amgen are trading down 5.5% over the last 24 hours, at...
Via
Benzinga
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
April 28, 2022
Via
Benzinga
Amgen's Return On Capital Employed Insights
April 28, 2022
Pulled from Benzinga Pro data, Amgen (NASDAQ:AMGN) posted Q1 earnings of $1.48 billion, an increase from Q4 of 22.27%. Sales dropped to $6.24 billion, a 8.88% decrease between quarters.
Via
Benzinga
Futures Rebound As Facebook Soars; Dollar Steamrolls Higher As Yen Crashes
April 28, 2022
U.S. index futures, European bourses, and Asian markets all rose as
Via
Talk Markets
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
April 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Amgen's Q1 Better Than Expected Sales, Profit Overshadowed By Tax Disclosure
April 28, 2022
Amgen Inc (NASDAQ: AMGN) has recently received a notice of deficiency from the Internal Revenue Service centered on 2013 to 2015.
Via
Benzinga
Recap: Amgen Q1 Earnings
April 27, 2022
Amgen (NASDAQ:AMGN) reported its Q1 earnings results on Wednesday, April 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Amgen beat estimated earnings by...
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.